ORNAV Stock Overview
Develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
My Notes
Capture your thoughts, links and company narrative
Orion Oyj Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €41.95 |
| 52 Week High | €49.85 |
| 52 Week Low | €32.50 |
| Beta | 0.35 |
| 1 Month Change | -5.41% |
| 3 Month Change | -10.74% |
| 1 Year Change | 8.40% |
| 3 Year Change | 17.84% |
| 5 Year Change | 1.57% |
| Change since IPO | 214.23% |
Recent News & Updates
Recent updates
Shareholder Returns
| ORNAV | FI Pharmaceuticals | FI Market | |
|---|---|---|---|
| 7D | -0.4% | -2.9% | -3.1% |
| 1Y | 8.4% | 3.1% | -7.5% |
Return vs Industry: ORNAV exceeded the Finnish Pharmaceuticals industry which returned 5.7% over the past year.
Return vs Market: ORNAV exceeded the Finnish Market which returned -6.8% over the past year.
Price Volatility
| ORNAV volatility | |
|---|---|
| ORNAV Average Weekly Movement | 3.4% |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.2% |
| 10% most volatile stocks in FI Market | 7.5% |
| 10% least volatile stocks in FI Market | 2.8% |
Stable Share Price: ORNAV has not had significant price volatility in the past 3 months compared to the Finnish market.
Volatility Over Time: ORNAV's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1917 | 3,867 | Liisa Hurme | www.orion.fi |
Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer. It also offers Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease.
Orion Oyj Fundamentals Summary
| ORNAV fundamental statistics | |
|---|---|
| Market cap | €5.93b |
| Earnings (TTM) | €331.70m |
| Revenue (TTM) | €1.43b |
17.9x
P/E Ratio4.2x
P/S RatioIs ORNAV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ORNAV income statement (TTM) | |
|---|---|
| Revenue | €1.43b |
| Cost of Revenue | €573.20m |
| Gross Profit | €856.00m |
| Other Expenses | €524.30m |
| Earnings | €331.70m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.36 |
| Gross Margin | 59.89% |
| Net Profit Margin | 23.21% |
| Debt/Equity Ratio | 27.8% |
How did ORNAV perform over the long term?
See historical performance and comparisonDividends
3.8%
Current Dividend Yield69%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 06:19 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Orion Oyj is covered by 18 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Graham Glyn Parry | BofA Global Research |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |